Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A phase 1b/2a randomized controlled, proof of concept trial to evaluate its efficacy of BGE-102 as a monotherapy and in combination with a VEGF inhibitor in patients with diabetic macular edema (DME)

Next Previous
Trial Profile

A phase 1b/2a randomized controlled, proof of concept trial to evaluate its efficacy of BGE-102 as a monotherapy and in combination with a VEGF inhibitor in patients with diabetic macular edema (DME)

Status: Planning
Phase of Trial: Phase I/II

Latest Information Update: 11 Feb 2026

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs BGE 102 (Primary)
  • Indications Diabetic macular oedema
  • Focus Proof of concept; Therapeutic Use

Most Recent Events

  • 11 Feb 2026 New trial record
  • 20 Jan 2026 According to a BioAge Labs media release, company plans to initiate this trial in mid-2026 and results are anticipated inmid-2027.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top